BACKGROUND: Allogeneic blood products transfusion during liver transplantation (LT) can be associated with increased morbidity and mortality. Data on thromboelastometry (ROTEM)-guided coagulation management with coagulation factor concentrates (CFCs)-fibrinogen concentrate and/or prothrombin complex concentrate (PCC)-are sparse. We aimed to retrospectively evaluate the safety events observed with this approach in our clinic. STUDY DESIGN AND METHODS: LT patients from January 2009 to December 2010 (n = 266) were identified by chart review. A ROTEM-based algorithm with CFC guided the hemostatic therapy. Doppler ultrasound was used to evaluate thrombosis in the hepatic artery, portal vein, and hepatic veins. Stroke, myocardial isch-emia, pulmonary embolism, and transfusion variables were recorded. Patients receiving CFC were included in the CFC group (n = 156); those not receiving CFC were included in the non-CFC group (n = 110). Safety events were compared between these two groups. RESULTS: Allogeneic transfusion(s) in the 266 patients was low, with medians of 2 (interquartile range [IQR], 0-5), 0 (IQR 0-0), and 0 (IQR 0-1) units for red blood cells (RBCs), fresh-frozen plasma (FFP), and platelets (PLTs), respectively. Ninety-seven of 266 LTs (36.5%) were performed without RBCs transfusion, 227 (85.3%) without FFP, and 190 (71.4%) without PLTs. There were no significant differences in thrombotic, thrombo-embolic, and ischemic adverse events occurrence between the CFC group and the non-CFC group (11/ 156 patients vs. 5/110; p = 0.31). CONCLUSION: In LT, ROTEM-guided treatment with fibrinogen concentrate and/or PCC did not appear to increase the occurrence of thrombosis and ischemic events compared to patients who did not receive these concentrates. T he median model of end-stage liver disease (MELD) score in EUROTRANSPLANT has increased from 25 to 35 (match-MELD) in the past 6 years, attributable to the adoption of MELD score as the basis for organ allocation in liver trans-plantation (LT). 1 This increase is associated with an increased risk of bleeding. 2 However, chronic liver disease is associated with multiple changes in coagulation status. On the one hand, the activity and levels of vitamin K-dependent coagulation factors (II, VII, IX, and X) and coagulation inhibitors (protein C and S) are decreased, as well as platelet (PLT) count. 3 Levels of tissue factor-expressing cells, von Willebrand factor, and coagulation Factor (F)VIII are often increased. 4,5 The concomitant reduction of pro-and anticoagulants typically leads to rebalanced hemostasis, but the low levels of pro-and anti-coagulants mean that the balance can be easily disturbed, ABBREVIATIONS: ALI = acute lung injury; aPTT = activated partial thromboplastin time; CFC(s) = coagulation factor concentrate(s); HAT = hepatic artery thrombosis; ICU = intensive care unit; INR = international normalized ratio; IQR = interquartile range; LT(s) = liver transplantation(s); MELD = median model of end-stage liver disease; PCC(s) = prothrombin complex concentrate(...